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Circulating gluten-specific forkhead box protein
3–positive CD391 regulatory T cells have impaired
suppressive function in patients with celiac disease
Q12 Laura Cook, PhD,a,b* C. Mee Ling Munier, PhD,a Nabila Seddiki, PhD,a,b David van Bockel, PhD,a
Noe Ontiveros, MSc,c,d Melinda Y. Hardy, PhD,c,d Jana K. Gillies, MSc,e Megan K. Levings, PhD,e
Hugh Reid, PhD,f Jan Peterson, PhD,f Jamie Rossjohn, PhD,f,g,h Robert P. Anderson, PhD,c,d,i
John Zaunders, PhD,a,b Jason A. Tye-Din, PhD,c,d,j and Anthony D. Kelleher, PhDa,b Sydney, Parkville, Clayton, and
Brisbane, Australia; Vancouver, British Columbia, Canada; Cardiff, United Kingdom; and Cambridge, Mass
Background: Celiac disease is a chronic immune-mediated
inflammatory disorder of the gut triggered by dietary gluten.
Although the effector T-cell response in patients with celiac
disease has been well characterized, the role of regulatory
T (Treg) cells in the loss of tolerance to gluten remains poorly
understood.
Objective: We sought to define whether patients with celiac
disease have a dysfunction or lack of gluten-specific forkhead
box protein 3 (FOXP3)1 Treg cells.
Methods: Treated patients with celiac disease underwent oral
wheat challenge to stimulate recirculation of gluten-specific T
cells. Peripheral blood was collected before and after challenge.
To comprehensively measure the gluten-specific CD41 T-cell
response, we paired traditional IFN-g ELISpot with an assay to
detect antigen-specific CD41 T cells that does not rely on
tetramers, antigen-stimulated cytokine production, or
proliferation but rather on antigen-induced coexpression of
CD25 and OX40 (CD134).
Results: Numbers of circulating gluten-specific Treg cells and
effector T cells both increased significantly after oral wheat
challenge, peaking at day 6. Surprisingly, we found that
approximately 80% of the ex vivo circulating gluten-specific
CD41 T cells were FOXP31CD391 Treg cells, which reside
within the pool of memory CD41CD251CD127lowCD45RO1
Treg cells. Although we observed normal suppressive function
in peripheral polyclonal Treg cells from patients with celiac
disease, after a short in vitro expansion, the gluten-specific
FOXP31CD391 Treg cells exhibited significantly reduced
suppressive function compared with polyclonal Treg cells.
Conclusion: This study provides the first estimation of
FOXP31CD391 Treg cell frequency within circulating gluten-
specific CD41 T cells after oral gluten challenge of patients with
celiac disease. FOXP31CD391 Treg cells comprised a major
proportion of all circulating gluten-specific CD41 T cells but
had impaired suppressive function, indicating that Treg cell
dysfunction might be a key contributor to disease pathogenesis.
(J Allergy Clin Immunol 2017;nnn:nnn-nnn.)
Key words: Regulatory T cells, CD39, forkhead box protein 3, celiac
disease, gluten, OX40
Celiac disease is a chronic inflammatory disorder with features
of autoimmune disease that results from a loss of gluten
tolerance.1 It is characterized by villous atrophy and the presence
of autoantibodies to tissue transglutaminase 2 (tTG), an enzyme
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Abbreviations used
APC: Antigen-presenting cell
CTV: CellTrace Violet
FOXP3: Forkhead box protein 3
PE: Phycoerythrin
SEB: Staphylococcal enterotoxin B
Tconv: Conventional T
Treg: Regulatory T
TSDR: Regulatory T cell–specific demethylated region
tTG: Tissue transglutaminase 2
that deamidates gluten. Intestinal damage is caused by CD41
T cells, which recognize deamidated gluten peptides presented
in complex with HLA-DQ2.5, HLA-DQ2.2, and/or HLA-DQ8,2,3
and the immunodominant hierarchy of wheat gliadin T-cell
epitopes in HLA-DQ2.51 patients with celiac disease has been
comprehensively mapped.4 Although HLA susceptibility
haplotypes are expressed by 30% to 40% of the general
population, celiac disease affects only approximately 1%,
indicating that immune tolerance to gluten is the norm. However,
the mechanisms that underpin maintenance of gluten tolerance
remain poorly described.
Gluten-responsive effector CD41 T cells can be detected in the
peripheral blood of patients with celiac disease on a gluten-free
diet 6 to 8 days after a 3-day oral gluten challenge.5 On
activation, these cells secrete high levels of IFN-g,6,7 support B
cell–mediated production of antibodies to tTG and modified
gluten peptides, and enhance lysis of stressed epithelial cells by
CD81 T cells.4,6 Studies of total regulatory T (Treg) cells in
patients with celiac disease have provided evidence for both
normal suppressive function8-10 and impaired function,11,12 as
well as suggesting that effector T cells have become resistant to
Treg cell suppression.10,13,14 However, although forkhead box
protein 3 (FOXP3)1 Treg cells have an important role in
maintaining peripheral tolerance, until now, the frequency and
function of gluten-specific FOXP31 Treg cells in patients with
celiac disease have not been studied.
For the first time, this study exploited acute in vivo gluten
challenge in patients with celiac disease to interrogate both
effector and regulatory components of the recall response to
gluten. Specifically, we aimed to estimate the frequency of Treg
cells within gluten-specific CD41T-cell recall responses; identify
changes in the frequency of peripheral gut-homing memory
CD41 T-cell populations after gluten challenge; and
phenotypically and functionally characterize gluten-specific
Treg cells.
METHODS
Subjects and samples
Patients with celiac disease were recruited after provision of informed
consent (Human Research Ethics Committees: Royal Melbourne Hospital ID
2003.009; Walter and Eliza Hall Institute of Medical Research ID 03/04).
Enrollment criteria were biopsy-proved disease conforming to European
Society for Paediatric Gastroenterology Hepatology and Nutrition
guidelines,15HLA-DQ21, and compliancewith a gluten-free diet for 6months
or more. Healthy donor blood was obtained from the Australian Red Cross
Blood Service and volunteers (St Vincent’s Hospital Human Research Ethics
Committee ID HREC/13/SVH/145). Peripheral blood was collected into
lithium heparin vacutainers (BD, San Jose, Calif), transported at ambient
temperature, and processed within 8 hours of collection. Mononuclear cells
were obtained by means of centrifugation over Ficoll-Paque (GE Healthcare,
Fairfield, Conn).
Serology and HLA typing
Serum titers of tTG IgA and deamidated gliadin peptide IgGwere evaluated
with commercial kits (INV 708760 and 704525; INOVA Diagnostics, San
Diego, Calif) by a diagnostic laboratory (Gribbles-Healthscope, nnn,
Australia) Q1. The presence of alleles encoding HLA-DQ2.5, HLA-DQ2.2, and
HLA_DQ8 was determined by detecting 5 single nucleotide polymorphisms
(rs2187668, rs2395182, rs4713586, rs7454108, and rs7775228), as previously
described.16,17 HLA-DQB1 and HLA-DQA1 alleles were determined by
using PCR sequence–specific oligonucleotide hybridization (Victorian
Transplantation and Immunogenetics Service, Victoria, Australia).
Oral gluten challenge
All participants undertook a gluten challenge5 from days 1 to 3 by
consuming 4 slices of commercial white bread daily (approximately 10 g/d
wheat gluten) and recorded symptoms daily to day 6, grading them as mild,
moderate, or severe.18
Reagents
We used 2 HLA-DQ2.5–restricted 15mers that encompass the
immunodominant deamidated wheat gliadin T-cell epitopes DQ2.5-glia-a1/
a2 (LQPFPQPELPYPQPQ) andDQ2.5-glia-v1/v2 (QPFPQPEQPFPWQP).4
Gluten peptide mix contained an equimolar mixture of these two 15mers. An
HLA-DQ2.5–restricted 15mer that encompasses the immunodominant barley
hordein T-cell epitope DQ2.5-hor-3 (PEQPIPEQPQPYPQQ) acted as a
specificity control.4 Peptides were synthesized to 95% purity or greater, as
confirmed by means of high-performance liquid chromatography (Pepscan,
Lelystad, The Netherlands); dissolved in dimethyl sulfoxide (Sigma-Aldrich,
St Louis, Mo); and stored at2808C until use.5,18 Chymotrypsin digestion and
deamidation of gliadin (#101778; ICN Biomedicals, Cost Mesa, Calif) were
performed, as previously described.5,18 Tetanus toxoid was from CSL (nnn,
Australia) Q2, and staphylococcal enterotoxin B (SEB) and PHA were from
Sigma-Aldrich.
IFN-g secretion assays
Antigen-stimulated IFN-g secretion from PBMCs was assessed by using
either ELISpot (Mabtech, Nacka Strand, Sweden) or ELISA (Mabtech),
assays that are equivalent in their ability to detect gluten-specific responses.18
Gluten peptide mix and deamidated gliadin were used at 100 mg/mL and
tetanus toxoid was used at 10 LfU/mL, and assays were performed in
triplicate, as previously described.5,18,19
OX40 assay
The OX40 assay was performed, as previously described,20,21 with either
fresh whole blood (diluted 1:1 with RPMI 1640 media, Invitrogen) or PBMCs
at 2 3 106 cells/mL and incubation with antigen for 44 hours at 378C (5%
CO2). Antigen concentrations were as follows: SEB, 1mg/mL; tetanus toxoid,
2 LfU/mL; deamidated gliadin, 100 mg/mL; and DQ2.5-hor-3m 50 mg/mL.
Optimal concentrations of gluten antigens were determined in a pilot study
(see Fig E1, B, in this article’s Online Repository at www.jacionline.org).
DQ2.5-glia-a1/a2 and DQ2.5-glia-v1/v2 were used separately at
50 mg/mL and in an equimolar gluten peptide mix. Assay cutoffs were as
follows: greater than 0.02% of CD41 T cells (mean1 3 SDs Q3of unstimulated
wells) and greater than 20 cells.
Population tracking within the OX40 assay
Postchallenge PBMCs were fluorescence-activated cell sorting purified
into 4 CD41 T-cell populations (Fig 3, A) Q4: (1) CD45RO2 T cells and
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(2) CD45RO1CD127highCD25low conventional T (Tconv) cells, with the
CD45RO1CD127lowCD25high Treg cells subdivided into (3) CD391 and
(4) CD392 cells. Portions of the 3 CD45RO1 populations were stained with
CellTrace Violet (CTV) to enable cell tracking. In some experiments
PBMCs were stained with DQ2.5-glia a21/a2 tetramer and sorted into
tetramer-negative and tetramer-positive CD41 T cells that were then labeled
with CTV. PBMCs were reconstituted, maintaining ex vivo cell ratios, and
supplemented with CD3-depleted autologous PBMCs (Dynabeads CD3,
Invitrogen) to one sixth of the total cell number. Each well contained a single
CTV-labeled population, and the OX40 assay was performed and analyzed, as
described above.
Flow cytometry
Staining was performed, as previously described,22 with anti-CD3–
peridinin-chlorophyll-protein complex–Cy5.5 (SK7), CD4–Alexa Fluor 700
(RPA-T4), CD25–allophycocyanin (2A3), OX40 (CD134)–phycoerythrin
(PE; L106), cytotoxic T lymphocyte–associated antigen 4–PE (BNI3),
GARP-BV711 (7B11), integrin b7–PE (FIB504; BD); CD45RO-ECD
(UCHL1; Beckman Coulter, Fullerton, Calif); CD127-eFluor450
(eBioRDR5), CD39-PECy7 (A1); LAP-PECy7Q5 (FNLAP; eBioscience),
Helios–Alex Fluor 488 (22F6), and anti-FOXP3–Alexa Fluor 488 (259D;
BioLegend, San Diego, Calif). FOXP3 staining was performed with the
FOXP3 buffer kit (BD), and the IgG1k-FITC antibody (BD) was used to set
analysis gates. All mAbswere used at manufacturers’ recommended dilutions.
Cell labeling was performed with the CTV Cell Proliferation Kit (Invitrogen)
and PKH26 Red Fluorescent Cell Linker Kit for General Cell Membrane
Labelling (Sigma-Aldrich) per the manufacturers’ recommendations by using
5 mmol/L dye concentrations. HLA-DQ2 proteins were synthesized with
bound DQ2.5-glia-a1, DQ2.5-glia-a2, or the HLA class II invariant peptide
by using previously described constructs and methods.23 Tetramers were
produced by means of addition of either NeutrAvidin R-allophycocyanin or
R-PE conjugate (Invitrogen) to biotinylated protein, as previously described.24
Staining was performed with 50 mg/mL tetramer in complete media at 378C
for 1 hour. A 4-laser LSRII flow cytometer (BD) was used, and analysis
was performed with FlowJo software (v8.8.7; TreeStar, Ashland, Ore).
In vitro expansion of T-cell populations
The protocol used to expand Treg cells, Tconv cells, and DQ2.5-glia-a1/
a2–specific CD391 T cells was adapted from Gregori et al,25 as previously
described20; T-cell cloning was performed by plating cells at 1 cell/well.
Irradiated feeder cell mix consisted of 5 3 105 cells/mL of mixed PBMCs
(equal mix of autologous PBMCs and PBMCs from 2 allogeneic healthy
donors) and 5 3 104 cells/mL of an autologous EBV-transformed B-cell
line generated and maintained, as previously described.26
Quantitative RT-PCR and T-cell receptor clonotype
analysis by 59 Rapid Amplification of cDNA Ends
Quantitative RT-PCR was performed on resting T-cell populations, and
relative expression levels to b-actin were calculated, as previously
described20: FOXP3 forward, 59-TCACCTACGCCACGCTCAT-39;
FOXP3 reverse, 59-TCATTGAGTGTCCGCTGCTT-39; TGF-b forward,
59-CCCTGGACACCAACTATTGC-39; and TGF-b reverse, 59-CAGA
AGTTGGCATGGTAGCC-39. T-cell receptor clonotypes were analyzed by
using 59RapidAmplification of cDNAEnds (Clontech,MountainView, Calif)
PCR, as previously described.27 Sequences were analyzed by using the
ImmunoGenetics V-quest database.28
Suppression assay
Suppression assays were performed, as previously described.20
CD41CD1271CD252 responder T cells were labeled with CTV (Invitrogen),
and suppressor cells were labeled with PKH26 (Sigma-Aldrich). Wells
contained 50,000 irradiated autologous antigen-presenting cells (APCs) and
20,000 responder T cells, with suppressor T cells added at the ratios indicated.
Assays were stimulated for 4 days with 0.25 mg/mL soluble anti-CD3
(Invitrogen). CD39 enzyme activity was blocked in some assays with
250 mmol/L ARL67156 (Sigma-Aldrich). The division index was used to
calculate the percentage of suppression.29
Treg cell–specific demethylated region analysis
Genomic DNAwas isolated, and bisulfite conversion was performed with
the EZ DNAMethylation-Direct kit (Zymo Research, Irvine, Calif). PCR was
performedwith the PyroMark PCR kit (Qiagen, Hilden, Germany) andHuman
FoxP3 Methylation Assay ADS783FS2 (EpigenDx, Ashland, Mass),
which reports the methylation of 8 representative CpG sites in the regulatory
T cell–specific demethylated region (TSDR). Pyrosequencing was performed
on a PyroMark Q96 ID (Qiagen) with PyroMark Gold Q96 reagents (Qiagen)
and Streptavidin Sepharose (GE Healthcare). All kits/reagents were used,
according to the manufacturer’s instructions. Analysis was performed on
female subjects, and the levels of methylation have not been adjusted to
account for X-inactivation.
Statistics
Mann-Whitney U tests or 1-way ANOVAwere used unless samples were
matched, and then Wilcoxon signed-rank tests were performed. Correlation
analyses used Spearman rho (rs). P values were considered significant at
less than .05. Prism 6.0 software (GraphPad Software, La Jolla, Calif) was
used for all statistical analyses.
RESULTS
Numbers of circulating gluten-specific
FOXP31CD391 Treg cells are significantly increased
after gluten challenge
To investigate CD41 T-cell recall responses to gluten, we
recruited a cohort of 17 treated patients with celiac disease
(see Tables E1 and E2 in this article’s Online Repository at
www.jacionline.org). We used our previously developed OX40
assay, which detects antigen-specific CD41 T cells through
antigen-induced coexpression of CD25 and OX40,21 to measure
changes in the frequency of circulating gluten-specific CD41
T cells in patients with celiac disease after gluten challenge
(Fig 1 [F1-4/C], A). In a pilot study we found the optimal time for detecting
responses was 6 to 8 days after gluten challenge (termed days 6
and 8; see Fig E1, A). At day 6, we observed significant increases
in deamidated gliadin levels (n5 15,P5.007) and gluten peptide
responses (n5 9,P5.008; Fig 1,B). The overall peak response to
gluten antigens occurred at day 6 (median response 0.27% of
CD41 T cells). There were no detectable responses to the barley
hordein peptide DQ2.5-hor-3 (Fig 1, A), indicating that the wheat
peptide responses are specifically induced by oral wheat gluten
challenge. Patients with detectable gluten peptide responses
also had a significant increase in numbers of both total and
gut-homing CD391FOXP31 Treg cells at day 6 (Fig 1,C), a trend
not seen in gluten peptide nonresponders (see Fig E2, A, in this
article’s Online Repository at www.jacionline.org). Q6There were
no significant changes observed within numbers of total or
gut-homing CD41 Tconv cells (data not shown).
We assessed the presence of gluten-specific CD41 T cells in 6
healthy volunteers (HLA-DQ genotypes were known for 4, and
only 1 carried HLA-DQ2.5). The median deamidated
gliadin-specific response for the non-HLA-DQ2.5 subjects was
0.09% of CD41 T cells (range, 0% to 0.15%), and the response
for all 6 subjects was 0.19% (range, 0% to 0.77%; see Fig E1,
C). No deamidated gluten peptide responses were detected in
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these subjects (data not shown), indicating that CD41 T-cell
responses to deamidated gluten peptides are a more specific
marker of celiac disease.
The majority of gluten peptide–specific
CD41CD251OX401 T cells express CD39
We have previously shown that within antigen-responsive
CD251OX401 T cells, a subset of Treg cells can be
identified on the basis of CD39 expression, providing a
sensitive and specific way to measure and isolate viable
antigen-specific FOXP31 Treg cells.20 We used this approach to
determine the contribution of CD391FOXP31 Treg cells to
gluten-specific OX40 assay responses (Fig 2[F2-4/C]
[F3-4/C]
, A). On average,
72% of deamidated gliadin-specific T cells were CD391
(75% coexpressed FOXP31), and 89% of gluten peptide-
specific T cells were CD391, with 82% of these cells expressing
FOXP3 (Fig 2, B).
We found similar CpG methylation patterns within the TSDR
in DQ2.5-glia-a1/a2–specific CD391 T cells sorted directly after
a 44-hour OX40 assay compared with ex vivo Treg cells
isolated from both healthy subjects and patients with celiac
disease (Fig 2, C). These data are consistent with gluten-
specific CD251OX401CD391 T cells being highly enriched for
Treg cells.
We confirmed OX40 assay specificity through several
experiments using DQ2.5-glia-a1/a2 tetramer reagents. We
costained DQ2.5-glia-a1/a2 peptide–stimulated OX40 assays
with DQ2.5-glia-a1/a2 tetramer and observed that of all
quadrants in the CD25 versus OX40 plot, the CD251OX401
quadrant had the highest proportion of tetramer-positive cells
(Fig 2, D). We confirmed that, similar to OX40 responses,
tetramer staining was only observed in day 6 postchallenge
PBMCs (not prechallenge PBMCs) and that the majority of the
CD41 tetramer-positive cells were CD391 (median, 70.3%;
n 5 7; Fig 2, E). Finally, we sorted CD41CD251OX401CD391
FIG 1. OX40 assay responses to gluten antigen peak at day 6 after gluten challenge. A, Representative OX40
assay responses from patients with celiac disease at day 6. B, For 15 patients with celiac disease, the
percentage of CD41 T cells responding to deamidated gliadin, gluten peptide mix, SEB, or tetanus toxoid
(Tet Tox) are shown. Dotted line, Assay cutoff. C, Flow cytometric analysis of total and integrin
b71CD391FOXP31 Treg cell (CD45RO1CD127lowCD25high) frequencies in ex vivo peripheral blood at days
0, 6, and 8 for patients with celiac disease and detectable gluten peptide responses (n 5 7). Red lines,
Patients with gluten peptide mix responses (n 5 9); black lines, patients with undetectable gluten peptide
responses (n 5 7). Statistical analyses used Wilcoxon signed-rank tests.
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T cells and labeled with cell proliferation dye before
restimulating with a panel of antigens in the presence of
autologous APCs. We observed that stimulation with cognate
antigen generated substantially more proliferation (87%)
than DQ2.5-glia-v1/v2 (29%), DQ2.5-hor-3 (29%), or no
antigen (21.7%). DQ2.5-glia-a1/a2 restimulation of matched
CD252OX402 T cells did not stimulate cell proliferation
(see Fig E3, D, in this article’s Online Repository at
www.jacionline.org).
Importantly, although CD39 expression varies between
subjects, in each subject the proportion of CD391 cells within
CD41T cells did not vary within the timeframe of theOX40 assay
(see Fig E4, C, in this article’s Online Repository at
www.jacionline.org). The proportion of CD391 cells within
recall responses also did not significantly vary from before
challenge through day 8 after challenge (see Fig E2, C, Online
Repository). Responses to the mitogen SEBwere similar between
the celiac cohort (n 5 15; mean response, 5.8% CD41 T-cells)
and healthy subjects (n 5 15; mean age, 37; 60% female; mean
response, 7.2% of CD41 T cells) and consisted of less than
30% CD391 T cells (20.7% in healthy subjects vs 29.1% in
patients with celiac disease; see Fig E2, E). This suggests that a
high proportion of CD391 cells within antigen-specific responses
is not an inherent feature of the OX40 assay but is instead a unique
FIG 2. The majority of circulating gluten peptide–specific CD41 T cells are CD391FOXP31. A and B, CD39
and FOXP3 expression within OX40 assay responses: representative data (Fig 2, A) and within responses
to deamidated gliadin (n 5 14) and gluten peptide mix (n 5 9; mean 6 SEM; Fig 2, B). C, Percentage
methylation at 8 CpG sites in the TSDR of FOXP3 within ex vivo Treg and Tconv cells (n 5 3 healthy female
subjects and n 5 3 female patients with celiac disease) and DQ2.5-glia-a1/a2–specific CD391 cells (n 5 3;
median 6 interquartile range). ns, Not significant. D, The frequency of DQ2.5-glia-a1/a2 tetramer-positive
cells is shown within each quadrant of the CD25/OX40 plot for DQ2.5-glia-a1/a2–stimulated OX40 assays
(n 5 3; mean 6 SEM). E, Representative DQ2.5-glia-a1/a2 tetramer and CD39 staining of unstimulated
PBMCs at days 0 and 6 after gluten challenge. For 3 patients, tetramer staining is shown at both day
0 and day 6. The proportion of tetramer-positive cells that are CD391 is shown for 7 patients with celiac
disease at day 6 after gluten challenge (mean 6 SEM). Statistical analyses in Fig 2, B and D, used
Mann-Whitney U tests, and those in Fig 2, E, used Wilcoxon signed-rank tests.
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feature of the recall response to gluten antigen in patients with
celiac disease.
To confirm that gluten-specific CD251OX401CD391 T cells
originated from the pool of circulating Treg cells, we used our
previously described method for population tracking within the
OX40 assay (Fig 3, A and B).20 We found that CD391 memory
Treg cells comprised an average of 88% of DQ2.5-glia-a1/a2-
specific CD251OX401CD391 T cells, with CD392 Treg cells
also the dominant population (average, 76%; n 5 4) within the
CD251OX401CD392 T cells (Fig 3, E). Again, we observed
that during a 44-hour OX40 assay, CD39 expression was not
affected by cell activation (Fig 3, C). For 2 subjects, we tracked
sorted, CTV-labeled CD41DQ2.5-glia-a1/a2 tetramer-positive
cells within OX40 assays stimulated with DQ2.5-glia-a1/a2
peptide. We observed that approximately 60% of the
CD251OX401 cells were composed of CD391CTV1 cells
(Fig 3, F). These data support our findings that peripheral
CD41CD45RO1CD25highCD127low Treg cells constitute more
than 80% of the total DQ2.5-glia-a1/a2–specific CD251OX401
T-cell response after gluten challenge.
FIG 3. DQ2.5-glia-a1/a2–specific CD251OX401CD391 T cells originate from peripheral CD391 Treg cells.
A and B, Overview of the method and gating strategy used to conduct population tracking within an
OX40 assay performed as described in the Methods section with peripheral blood after gluten challenge.
C, Changes in CD39 expression between ex vivo isolation and after a 44-hour OX40 assay for Tconv cells,
CD392 Treg cells, and CD391 Treg cells (mean 6 SEM). D, Representative plots for unstimulated wells
and DQ2.5-glia-a1/a2–stimulated wells that contained CTV-labeled CD391 Treg cells. E, Proportion of Tconv
cells (gray), CD392 Treg cells (blue), and CD391 Treg cells (red) within the total DQ2.5-glia-a1/a2–specific
CD251OX401 T-cell response and the CD392 and CD391 fractions of this response. Data in Fig 3, C and E,
are the mean of 5 independent experiments with 4 patients with celiac disease. F, Tetramer-positive cells
were sorted from day 6 PBMCs, labeled with CTV, and either left unstimulated or stimulated for 44 hours
with DQ2.5-glia-a1/a2 peptide in the presence of autologous APCs. The proportion of CD391CTV1 cells
within the CD251OX401 quadrant is representative of 2.
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DQ2.5-glia-a1/a2–specific CD391 T cells have
impaired suppressive function
DQ2.5-glia-a1/a2–specificCD41CD251OX401CD391Tcells
were expanded in vitro from post–gluten challenge PBMCs (sort
purities, >90%) to further investigate the phenotype and function
of gluten-specific FOXP31CD391 Treg cells. For female
patients with celiac disease and healthy donors, we also expanded
non–gluten-specific CD252OX402 T cells and, from unstimulated
PBMCs, CD25highCD127lowTreg cells and CD252CD1271Tconv
cells. We generated 3 T-cell clones, 2 from patient #0174 (C1
and C2) and 1 from patient #0251 (C3). Clonality was
confirmed through sequencing the T-cell receptor b chain variable
region. Both T-cell clones from patient #0174 expressed the
same TRBV7-2 clonotype (CASSLRYTDTQYF), which might
be a public clonotype, as previously identified in another celiac
cohort.30
Suppression assays used soluble anti-CD3 stimulus for 4 days
in the presence of autologous APCs with a 1:1 ratio of suppressor
to responder cells (Fig 4[F4-4/C] , A). Suppressive function of ex vivo
celiac Treg cells (CD25highCD127low; median, 73.4%; n 5 5)
before oral gluten challenge was comparable with that of healthy
Treg cells (median, 70.5%; n 5 6) but significantly greater than
that of Tconv cells (CD252CD1271; median, 12%; n 5 5), as
expected (P 5 .016; Fig 4, B). Interestingly, the subset of
ex vivo CD25highCD127low Treg cells that was isolated as
CD391 cells before challenge had reduced suppressive function
(median, 46.3%; n 5 5; P 5 .016) that was not further affected
by the CD39 inhibitor ARL67156 (median, 45.5%). Similarly,
56-day expanded DQ2.5-glia-a1/a2–specific CD391 T cells
had slightly reduced suppression comparedwith ex vivoTreg cells
from patients with celiac disease (mean, 55.8%; range, 30.1% to
74.8%), as did the CD391 T-cell clones C1 and C2 (62% and 52%
suppression, respectively; Fig 4, C). Addition of the CD39
inhibitor ARL67156 had a minimal effect (mean reduction in
suppression, 11%; Fig 4, C).
We assessed in vitro suppressive function with suppressor/
responder cell ratios of 1:1 to 1:32 for 14 days expandedQ7 :
DQ2.5-glia-a1/a2–specific CD391 T cells (n5 4), a T-cell clone
(C3), and, for 4 healthy subjects and patients with celiac disease,
Treg cells (CD25highCD127low) and Tconv cells
(CD252CD1271). The celiac Treg cells exerted suppression
across all cell ratios comparable with that of Treg cells from
healthy subjects, whereas the gluten-specific CD391 T-cell clone
C3 began to exhibit markedly lower suppressive function at a
1:8 cell ratio (Fig 4, D). The expanded gluten-specific CD391
T cells had significantly reduced suppressive function compared
with that of polyclonal Treg cells from both healthy
subjects and patients with celiac disease across all ratios tested
(Fig 4, D). These data indicate that in patients with celiac disease
after gluten challenge, the expanded subset of peripheral
gluten-specific CD391 Treg cells, but not polyclonal Treg cells,
has impaired suppressive function.
Approximately 50% of expanded gluten-specific
CD251OX401CD391 T cells stained positive for DQ2.5-
glia-a1/a2 tetramer compared with greater than 2%
tetramer-positive cells within non–gluten-specific CD252OX402
T cells (see Fig E3, B). These cells had substantial expression of
CD39, CD25, cytotoxic T lymphocyte–associated antigen 4, and
integrin b7, but FOXP3 expression was low or absent (see Table
E3 in this article’s Online Repository at www.jacionline.org).
Interestingly, gluten-specific CD391 T cells were Helios
negative, suggesting they originate from a peripherally derived
Treg cell population (see Fig E3, C). Quantitative RT-PCR
confirmed that expanded gluten-specific CD391 T cells had
very low levels of FOXP3 and moderate-to-high levels of
TGF-b expression that corresponded to increased surface
expression of GARP and LAP, which tether latent TGF-b to the
cell membrane (see Fig E3, A and E). Loss of FOXP3
protein expression corresponded to increased CpG methylation
in the TSDR of expanded cells. CD391 T cells had an
average 2.8-fold increase in methylation, whereas Treg
cells from healthy subjects and patients with celiac disease
had 1.5- and 1.4-fold increases in methylation, respectively (see
Fig E3, F).
Antigen-stimulated expression of CD25 and OX40
detects significantly more gluten-specific T cells
than conventional IFN-g secretion assays
We performed correlation analyses to compare the sensitivity
of the OX40 assay with that of conventional IFN-g ELISpot
assays. We observed a positive correlation between the IFN-g
ELISpot assay at day 6 and peak OX40 assay responses to gluten
peptide stimulus (n 5 13, rs 5 0.876, P 5 .0002; Fig 5 ½F5, A, and
Table I ½T1). For the 12 HLA-DQ2.5 patients with celiac disease
and detectable IFN-g responses to gluten peptide antigen, 10
(83%) also had detectable OX40 assay responses. A linear
regression analysis of responses to gluten peptide antigen
detected by using each assay generated a line of best fit with a
slope (m) of 4.806. This indicates the OX40 assay detects
approximately 5 times the number of gluten peptide–specific
CD41 T cells than the IFN-g ELISpot (Fig 5, B).
A high proportion of memory Treg cells from
patients with celiac disease express CD39
Flow cytometry was used to measure the frequency of
peripheral lymphocyte populations (see gating in Fig E4, B) in
healthy volunteers (n 5 13; mean age, 47; 69% female) and
patients before gluten challenge (n 5 13; mean age, 58;
69% female). The proportion of CD391 cells within memory
Treg cells was significantly higher in patients (mean,
74.65%; range, 59.7% to 83.7%) than healthy control subjects
(mean, 48.07%; range, 11.10% to 73.30%; P < .0001; Fig 5,
C). Patients with celiac disease also had significantly reduced
total memory Treg cell numbers at day 0 (mean, 3.14% of
CD41 T cells) compared with healthy control subjects
(mean, 7.97%; P < .0001; Fig 5, D), which persisted at days
6 and 8 after challenge (data not shown), and significantly
more CD391 memory Treg cells within CD41 T cells at day
0 (P 5 .037; Fig 5, E).
Symptom severity associated with stronger gluten
peptide recall responses in the OX40 assay
Patients with celiac disease were split into 2 groups based on
their symptom severity to identify associations between
immunologic variables and clinical symptoms (Table I). No
significant differences were observed for the frequency of total
CD45RO1CD391 Treg cells at day 0 or for ELISpot responses
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to gluten peptide mix (see Fig E5, A and C, in this article’s Online
Repository at www.jacionline.org). However, patients with celiac
disease andmore severe symptoms had significantlymore CD391
cells within deamidated gliadin-specific CD251OX401 T cells
(P 5 .014) and significantly larger OX40 assay responses to
gluten peptides (P 5 .011; see Fig E5, B and D).
DISCUSSION
These data are the first report of the contribution of
FOXP31CD391 Treg cells to gluten-specific CD41 T-cell
responses in patients with celiac disease after in vivo gluten
challenge. Surprisingly, we observed that FOXP31CD391
Treg cells comprised more than 80% of circulating gluten
FIG 4. In vitro–expanded DQ2.5-glia-a1/a2–specific T cells retain suppressive function. A, Representative
responder cell proliferation showing division index (DI). B, Percentage of suppression of ex vivo Treg cells
from healthy subjects (n 5 6), Treg cells from patients with celiac disease (n 5 5), CD391 Treg cells from
patients with celiac disease (n 5 5), and Tconv cells from patients with celiac disease (n 5 5) at a 1:1 ratio
with responder T cells. ns, Not significant. C, Percentage suppression of 56-day expanded DQ2.5-glia-a1/a2–
specific CD391 T-cell populations (n5 2) and CD391 T-cell clones (C1 and C2). The CD39 inhibitor ARL67156
was added as indicated. D, Percentage suppression of 14-day expanded Treg cells (n 5 4), Tconv cells
(n 5 4), and DQ2.5-glia-a1/a2–specific CD391 T cells (n 5 4) from healthy subjects and patients with celiac
disease and T-cell clone C3 for 1:1 to 1:32 suppressor/responder cell ratios. Data in Fig 4, B-D, are
medians 1 interquartile ranges Q8of 1 to 3 independent experiments, and statistical analyses used
Mann-Whitney U tests.
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peptide–specific CD41T cells in patients with celiac disease after
gluten challenge. We confirmed that more than 85% of the gluten
peptide–specific FOXP31CD391 T cells originated from the
peripheral pool of CD391 Treg cells and that the extent of CpG
methylation in the TSDR within the FOXP3 loci of these cells
is similar to that seen in CD127lowCD25high Treg cells from
healthy subjects.
Because the majority of FOXP31 Treg cells do not secrete
IFN-g, our data indicate that IFN-g–based methods only detect
approximately 20% of the total CD41 T-cell response to gluten
antigen (supported by our linear regression analysis). The
OX40 assay correlated with the IFN-g ELISpot for the detection
of gluten-specific CD41 T-cell responses. This concurs with
previous studies that found the OX40 assay has strong agreement
with IFN-g release assays for Mycobacterium tuberculosis31,32
and concordance with serology, proliferation, and cytokine
responses to HIV-1,21 hepatitis C virus,33 human papilloma-
virus,34 Mycobacterium avium complex, varicella zoster
virus, EBV, CMV, Candida albicans, and Streptococcus
pneumonia.21,35 For the first time, we also show that the OX40
assay corresponds with class II tetramer staining for responses
to the DQ2.5-glia-a1/a2 epitopes in patients with celiac disease
after gluten challenge.
These data complement our previous study showing that
CD391 Treg cells comprise a substantial proportion of CD41
T-cell recall responses to viral and bacterial antigens.20 Previous
studies of FOXP31 Treg cells within in vivo recall responses to
varicella zoster virus in human subjects36,37 and within secondary
immune responses to influenza virus in mice38,39 identified a key
role for pathogen-specific Treg cells in controlling the cellular im-
mune response. Of particular interest is the recent discovery that
particle-associated antigens drive a Treg cell response, whereas
distinct soluble antigens instead drive an effector T-cell
response.40 In addition to the type of antigen, the balance between
Treg and Tconv cells within antigen-specific responses is also
influenced by chronicity of antigen exposure.41 This study is a
large contribution to the relatively underexplored area of
antigen-specific human Treg cells and shows that, for patients
with celiac disease on a gluten-free diet, the CD41 T-cell
response to acute dietary gluten re-exposure is skewed toward
FIG 5. Analysis of assay correlation and peripheral Treg cell frequency and phenotype. A and B, Gluten
peptide mix IFN-g ELISpot responses (SFU/106 PBMCs; n 5 13) are correlated with OX40 assay responses
(n 5 13) expressed as either CD251OX401 cells as a percentage of CD41 T cells (Fig 5, A) or CD251OX401
cells/106 PBMCs (Fig 5, B). In Fig 5, A, the calculated Spearman rho (rs) and P values are shown, and in Fig 5,
B, the line of best fit (solid line) and 95% CIs (dashed line) are shown. C-E, Flow cytometric phenotyping data
from 13 patients with celiac disease were compared with those in healthy subjects (n 5 13) for the
proportion of CD41CD45RO1CD127lowCD25high Treg cells that expressed CD39 (Fig 5, C), the proportion
of CD45RO1 Treg cells within CD41 T cells (Fig 5, D), and the proportion of CD41 T cells that were
CD45RO1CD391 Treg cells (Fig 5, E). Error bars represent medians 6 interquartile ranges, and statistical
analyses used Mann-Whitney U tests.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
COOK ET AL 9
FLA 5.4.0 DTD  YMAI12681_proof_–15-00411  20 March 2017  12:51 pm
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
Treg cells. Furthermore, we demonstrate that functional
defects can be unmasked by studying the relevant disease
antigen-specific population rather than polyclonal Treg cells.
On average, maximal OX40 responses to gluten antigens
occurred at day 6 after gluten challenge, a similar time course
to that previously noted for IFN-g responses.7,18 These dynamic
changes were restricted to the gluten-derived antigens because
there was little change in responses to mitogen or control
antigens. Importantly, CD391 proportions within all OX40 assay
responses were not significantly altered after gluten challenge,
indicating the high CD391 proportions observed within gluten
peptide responses occur independently of immune activation.
For those patients with celiac disease who did not respond to
the gluten peptides in this study, there is no evidence of durable
immune tolerance because the gluten challenge still caused
clinical symptoms for these patients. It is more likely that the
immune response is present but either less than the assay’s limit
of detection or not detectable in peripheral blood. The severity
of gastrointestinal symptoms also corresponded to larger immune
responses to gluten and a higher frequency of CD391 cells within
these responses. This is similar to a previous observation that the
density of intestinal FOXP31Treg cells positively correlated with
the severity of histologic damage.10
Both expanded DQ2.5-glia-a1/a2–specific CD391 T-cell lines
and clones and total ex vivo CD391 Treg cells from patients with
celiac disease had reduced suppressive function in response to a
polyclonal stimulus that was not dependent on CD39 function
but corresponded to a loss of stable FOXP3 expression, indicating
that gluten-specific CD391 Treg cells from patients with celiac
disease might have an inherent functional defect. These data
contrast with a previous observation that found expanded
IL-10–secreting gluten-specific Treg type 1 cell clones had
normal in vitro suppressive function.8 Our in vitro–expanded
DQ2.5-glia-a1/a2–specific CD391 T cells had a
CD251FOXP32TGF-b1GARP1LAP1 phenotype that most
closely resembles that of human regulatory TH3 cells.
42 In
contrast to the previously observed stable FOXP3 expression
seen in expanded CMV-P1–specific T-cell clones,20 expanded
gluten-specific CD391 T-cell populations lost FOXP3 expression
in vitro within 14 days, which corresponded to increased CpG
methylation in the TSDR. This might indicate that
gluten-specific CD391 Treg cells retain a high degree of
plasticity,43 although expanded healthy Treg cells also acquired
methylation in vitro to a lesser extent.
Compared with healthy control subjects, patients with celiac
disease before challenge had significantly more CD391 cells
within CD45RO1 Treg cells yet lower absolute numbers of
CD45RO1 Treg cells. This is likely due to a single nucleotide
polymorphism in the CD39 gene that determines CD39
expression levels in Treg cells, and futurework should investigate
the association of such CD39 single nucleotide polymorphisms
with celiac disease.44 CD391 Treg cells have been shown to be
potent suppressors of IFN-g and IL-17 and to be increased in
the synovia of patients with juvenile arthritis.44 Therefore
CD391 Treg cells might be preferentially expanded, yet their
numbers are insufficient to control inflammation after gluten
exposure in patients with celiac disease. CD39 expression on
Treg cells might also be useful in predicting clinical outcomes
TABLE I. Celiac disease cohort symptoms and CD41 T-cell responses to gluten antigens Q9
ID Symptoms after gluten challenge
Post–gluten challenge
gluten peptide mix response,
OX40 assayz
Post–gluten challenge
gluten peptide mix response,
IFN-g secretion
0062* Mild depressed mood and lethargy (days 4-6) Detected Detected
0077* Asymptomatic Not detected§ Detected
0080* Mild nausea (days 1-3) Not detected Not detected
0152 Severe vomiting, lethargy, and diarrhea (days 1-3); moderate nausea, bloating,
and abdominal pain (days 1-3)
Detected Detected
0159* Mild bloating, abdominal pain, and lethargy (days 2-3) Detected Detected
0174 Severe nausea, vomiting, abdominal pain, and diarrhea (days 1-3); moderate
lethargy, hot flushes, cold sweats, and flatulence (days 2-4)
Detected Detected
0196 Moderate-to-severe abdominal pain, nausea, and lethargy and mild diarrhea
(days 1-3)
Detected Detected (ELISA)
0230* Mild nausea and diarrhea (days 1-3) Detected Detected
0239* Asymptomatic Not detected Detected (at assay
limit of detection)
0250 Severe vomiting, nausea, abdominal pain, lethargy, and cold sweats
(days 1-3); mild bloating and diarrhea (days 2-4)
Detected Detected
0251 Moderate-to-severe abdominal pain, bloating, nausea, and lethargy Detected Detected (ELISA)
0505* Severe lethargy and mild diarrhea (days 1-3) Not detected Not detected
0506* Mild constipation (days 1-3) Not detected Not detected
0509* Mild bloating, abdominal pain, and diarrhea (day 1) Not detected Not detected
0510 Severe bloating, abdominal pain, and constipation (days 203) Not detected Not detected
0512* Asymptomatic Detected Detected
0072 Moderate-to-severe nausea, bloating, and vomiting (day 1);
moderate abdominal pain and lethargy (day 1)
Detected Detected
*Nonsevere group: reported mild or no symptoms.
Severe group: reported moderate-to-severe symptoms.
Post–gluten challenge OX40 assay responses were only listed as detected if they were greater than the baseline response.
§Cohort analyses were performed with 15 patients: patient #0077 was not included because day 8 OX40 assays used cryopreserved PBMCs, and patient #0072 was not included
because day 8 analysis was not performed.
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because low CD39 expression has been associated with better
CD41 T-cell recovery after antiretroviral therapy in HIV1
patients20 and methotrexate resistance in patients with
rheumatoid arthritis.45
Together, the data presented here indicate that in patients with
celiac disease after gluten challenge, FOXP31CD391 Treg cells
dominate peripheral recall responses to gluten and can be readily
expanded on in vivo antigen challenge yet exhibit impaired
in vitro suppressive function. Therefore one interpretation of
these data is that, in response to gluten challenge,
FOXP31CD391 Treg cells are induced in vivo in an attempt to
restore homeostasis. However, the generated cells have impaired
suppressive function, possibly as a result of generation under
inflammatory conditions in vivo. A key area for further
investigation is whether in vivo challenge conditions could be
manipulated to drive expansion of functional Treg cells.
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Key messages
d In patients with celiac disease, 6 days after gluten
challenge in vivo, a surprisingly large proportion of
circulating gluten-specific CD41 T cells are FOXP31
CD391 Treg cells.
d In patients with celiac disease after gluten challenge,
gluten-specific Treg cells exhibit impaired polyclonal sup-
pressive function in vitro, suggesting that an intrinsic
dysfunction of expanded CD391 Treg cells might
contribute to the loss of tolerance to gluten.
d Detection of gluten-specific CD41 T cells based on
antigen-induced coexpression of CD25 and OX40 is
more sensitive than traditional methods relying on
antigen-induced cytokine production and, for the first
time, allows detailed characterization of antigen-specific
Treg cells in patients with this disease.
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FIG E1. Optimization of OX40 assay time course and gluten antigen concentration. A, In a pilot study OX40
assays were performed with peripheral blood from 3 patients (#0080, #0152, and #0250) and 1 HLA-DQ21
subject without celiac disease (#0458). Blood was collected before gluten challenge (day 0) and at days 4,
6, 8, and 10 after challenge. OX40 assay responses (CD251OX401) are shown for gluten peptide mix,
DQ2.5-glia-a1/a2, DQ2.5-glia-v1/v2 deamidated gliadin, SEB, or tetanus toxoid (Tet Tox). B, OX40 assay
responses are shown at days 6 and 8 to 10, 50, and 100 mg/mL deamidated gliadin; 50 and 125 mg/mL
DQ2.5-glia-a1/a2; or 50 and 125 mg/mL DQ2.5-glia-v1/v2. C, OX40 assays were performed with peripheral
blood of 6 healthy subjects. The deamidated gliadin responses are shown for a single experiment with
each subject. Error bars represent means 6 SEMs.
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FIG E2. Changes in peripheral Treg cell frequencies and OX40 assay CD391 proportions after gluten
challenge. A and B, Frequencies of CD41 T cells that were memory CD391FOXP31 Treg cells (Fig E3, A)
and integrin b71CD391 memory Treg cells (Fig E3, B) are shown for patients who did not have detectable
gluten peptide responses (n 5 6). C, The proportion of CD39 expression within OX40 assay responses is
plotted for assays stimulated with SEB (n 5 15), tetanus toxoid (Tet Tox; n 5 15), deamidated gliadin
(n 5 10), and gluten peptide mix (n 5 7). Subjects were only included in analyses if they had detectable
responses at all 3 time points or, for gluten peptide mix, if they had detectable responses at both day 6
and day 8. Statistical analyses were performed with Wilcoxon signed-rank tests. ND, Not detected; ns,
not significant. Each subject is represented by a different symbol, and red connecting lines indicate those
subjects with gluten peptide responses. D and E, Total CD41CD251OX401 T-cell responses to SEB and
the proportion of CD391 cells within these responses are shown for healthy subjects (n 5 15; Fig E3, D)
and patients with celiac disease (n 5 15; Fig E3, E). Means 6 SEMs are shown.
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FIG E3. Characterization of expanded DQ2.5-glia-a1/a2–specific CD391 T cells. A, Quantitative RT-PCR was
used to compare FOXP3 and TGF-b mRNA expression levels in 14-day expanded gluten-specific CD391 T
cells to levels in expanded CD127lowCD25high Treg cells from healthy subjects (n 5 3) and expanded Treg
and CD1271CD252 Tconv cells from patients with celiac disease (n 5 2). Relative expression is shown after
normalization to b-actin. Means 6 SEMs are shown for 2 independent experiments. B, DQ2.5
tetramer (loaded with HLA class II invariant peptide or DQ2.5-glia-a1/a2) staining of 14-day expanded
DQ2.5-glia-a1/a2–specific CD251OX401 and non–gluten-specific CD252OX402 T cells. Frequencies of
tetramer-positive cells are representative of expanded CD391 cells and clones from 2 subjects. C, CD39
and Helios staining (representative of n 5 3) of expanded CD127lowCD25high Treg cells and
gluten-specific CD391 T cells from healthy subjects and patients with celiac disease. D, DQ2.5-glia-a1/a2–
specific CD251OX401CD391 (red) and non–gluten specific CD252OX402 (black) T cells were
fluorescence-activated cell sorting isolated directly after an OX40 assay and restimulated for 5 days with
the antigens indicated. Percentage proliferation shown is representative of 3 subjects. E, Histograms
showing expression of GARP and LAP in cells expanded from patient #0251 with celiac disease and a
healthy control subject. Median fluorescence intensity (MFI) Q10is shown in the legend. F, Percentage
methylation in the TSDR of FOXP3 is shown for 14-day expanded CD127lowCD25high Treg cells from healthy
subjects (n 5 3) and patients with celiac disease (n 5 3) and gluten-specific CD391 T cells (n 5 3;
median 6 interquartile range; all donors were female). ns, Not significant.
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FIG E4. Flow cytometric gating strategies. A, Gating strategy for OX40 assay analysis. Lymphocytes were
gated based on their forward- and side-scatter profiles, followed by gating CD31CD41 T cells. The
crosshatch gates used to define the antigen-specific CD251OX401 T cells were set initially on unstimulated
wells and refined by using responses in SEB-stimulated positive control wells. B,Gating strategy shown for
isolation and phenotypic analysis of peripheral CD41 memory T-cell populations. After gating on
lymphocytes and CD31CD41 T cells, the CD45RO1 memory cells were divided into Treg cells
(CD127lowCD25high) and the remaining non-Treg cells, with the Treg cells separated further into CD391
and CD392 populations. Expression of phenotypic markers, such as the gut-homing marker integrin b7,
was analyzed within each gated T-cell population. C, For 12 patients with celiac disease, the percentage
of CD391 cells within CD41 T cells is shown for PBMCs sourced directly ex vivo and from OX40 assay wells
after 44 hours of stimulation with no antigen, SEB, or gluten peptide mix.
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FIG E5. Symptom severity associated with greater responses to gluten peptide antigen. Patients with celiac
disease were divided into groups based on symptom severity: severe, n 5 7; nonsevere, n 5 10. Groups
were compared by identifying differences in the proportion of CD391 cells within ex vivomemory Treg cells
(A), the proportion of CD39 expression within deamidated gliadin-specific CD251OX401 T cells (B), the
magnitude of day 6 postchallenge IFN-g ELISpot response to gluten peptide mix (n 5 5 in severe group
because n 5 2 only had ELISA data; (C), and the maximal OX40 assay response to gluten peptide mix
(D). Error bars represent means 6 SEMs. Mann-Whitney U tests were performed. ns, Not significant.
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TABLE E1. Celiac disease cohort characteristics
ID Age (y) Sex Time since diagnosis tTG IgA (U/mL)* DGP IgA (U/mL)* HLA-DQ Haplotype
0062 66 F 5 y, 9 mo <20 <20 HLA-DQ2.5
0077 48 M 21 y <20 <20 HLA-DQ2.5
0080 68 F 31 y <20 <20 HLA-DQ2.5
0152 54 M 1 y, 9 mo <20 <20 HLA-DQ2.5
0159 67 F 14 y, 9 mo <20 <20 HLA-DQ2.5 (homozygous)
0174 51 F 15 y, 7 mo <20 <20 HLA-DQ2.5
0196 60 F 9 y, 3 mo <20 <20 HLA-DQ2.5
0230 53 F 12 y, 9 mo <20 <20 HLA-DQ2.5
0239 71 F 39 y, 3 mo <20 <20 HLA-DQ2.5 (homozygous)
0250 62 M 8 y, 5 mo <20 <20 HLA-DQ2.5
0251 53 F 8 y, 2 mo <20 <20 HLA-DQ2.5
0505 35 F 34 y, 11 mo <20 <20 HLA-DQ2.2
0506 69 M 2 y, 1 mo <20 <20 HLA-DQ2.5 (heterozygous)
0509 29 F 7 y, 11 mo <20 <20 HLA-DQ2.5 (heterozygous)
0510 38 M 4 y, 11 mo 62 (strongly positive) 27 (weakly positive) HLA-DQ2.5 and HLA-DQ2.2
0512 52 F 1 y, 4 mo <20 29 (weakly positive) HLA-DQ2.5 (heterozygous)
0072 57 F 20 y, 2 mo <20 <20 HLA-DQ2.5 (heterozygous)
Mean 55 71% F
29% M
14 y, 1 mo <20 <20
All data were collected at the time of gluten challenge. All subjects have been on a gluten-free diet since diagnosis.
DGP, Deamidated gliadin peptide; F, female; M, male.
*Normal serology is less than 20 U/mL.
Indicates subjects analyzed in the pilot study.
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TABLE E2. HLA-DQ alleles detected in the celiac disease
cohort
ID HLA-DQA HLA-DQB
0062 DQA1*05 DQB1*02
DQB1*03
0077 DQA1*01
DQA1*05
DQB1*02
DQB1*05
0080* DQA1*05:01 DQB1*02:01
DQB1*02:02
0152* DQA1*01
DQA1*05
DQB1*02
DQB1*06
0159 DQA1*05:01 DQB1*02:01
0174 DQA1*05:01 DQB1*02:01/02
DQB1*05:02
0196 DQA1*05:01 DQB1*02:01/02
DQB1*06:02
0230 DQA1*05:01 DQB1*02:01
DQB1*05:02
0239 DQA1*05:01 DQB1*02:01
0250* DQA1*02
DQA1*05
DQB1*02
0251 DQA1*01
DQA1*05
DQB1*02:01
DQB1*05:01
0505 DQA1*02
DQA1*04/06
DQB1*02
DQB1*04
0506 N/A N/A
0509 N/A N/A
0510 DQA1*02:01
DQA1*05:01
DQB1*02:01
DQB1*02:02
0512 NA NA
0072 NA NA
HLA-DQ2.5 refers to the DQA1*0501:DQB1*0201 haplotype, and HLA-DQ2.2
refers to the DQA1*0201:DQB1*0202 haplotype.
NA, HLA-DQB1 and HLA-DQA1 alleles were not assessed, and instead only the
presence of alleles encoding HLA-DQ2.5, HLA-DQ2.2, and HLA-DQ8 were detected,
as described in section 2.4.Q11
*Indicates subjects analyzed in the pilot study.
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TABLE E3. Phenotype of in vitro–expanded DQ2.5-glia-a1/a2–specific CD41CD251CD1341CD391 T cells
Molecule Clone C1 (#0174) Clone C2 (#0174) Clone C3 (#0251) CD391 cells (#0174) CD391 cells (#0230) CD391 cells (#0196) CD391 cells (#0251)
CD25 111 111 111 111 111 111 111
CD39 111 111 111 111 111 111 111
FOXP3 1 2 11 1 2 1 1
CTLA-4 111 111 11 111 111 11 111
CD45RO 111 111 111 111 111 111 111
Integrin b7 11 11 11 11 111 1 1
LAP NA NA 111 NA NA 1 1
GARP NA NA 11 NA NA 11 11
Helios NA NA 2 NA NA 2 2
CTLA-4, Cytotoxic T lymphocyte–associated antigen 4; NA, not assessed; 111, expression on greater than 90% of cells; 11, expression on 50% to 90% of cells; 1, expression
on 10% to 50% of cells; 2, expression on less than 10% of cells.
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